Literature DB >> 26811226

Trends in Subpopulations at High Risk for Lung Cancer.

Ping Yang1, Yi Wang2, Jason A Wampfler3, Dong Xie4, Shawn M Stoddard2, Jun She5, David E Midthun6.   

Abstract

INTRODUCTION: Two-thirds of patients in the United States with newly diagnosed lung cancer would not meet the current U.S. Preventive Services Task Force (USPSTF) screening criteria, which suggests a need for amendment of the definition of high risk. To provide evidence of additional high-risk subpopulations and estimated gains and losses from using different criteria for screening eligibility, we conducted a two-step study using three cohorts.
METHODS: The two prospective cohorts comprised 5988 patients in whom primary lung cancer was diagnosed between 1997 and 2011 (the hospital cohort) and 850 defined-community residents (the community cohort); the retrospective cohort consisted of the population of Olmsted County, Minnesota, which was observed for 28 years (1984-2011). Subgroups of patients with lung cancer who might have been identified using additional determinates were estimated and compared between the community and hospital cohorts. The findings were supported by indirect comparative projections of two ratios: benefit to harm and cost to effectiveness.
RESULTS: Former cigarette smokers who had a smoking history of 30 or more pack-years and 15 to 30 quit-years and were 55 to 80 years old formed the largest subgroup not meeting the current screening criteria; they constituted 12% of the hospital cohort and 17% of community cohort. Using the expanded criteria suggested by our study may add 19% more CT examinations for detecting 16% more cases when compared with the USPSTF criteria. Meanwhile, the increases in false-positive results, overdiagnosis, and radiation-related lung cancer deaths are 0.6%, 0.1%, and 4.0%, respectively.
CONCLUSIONS: Current USPSTF screening criteria exclude many patients who are at high risk for development of lung cancer. Including individuals who are younger than 81 years, have a smoking history of 30 or more pack-years, and have quit for 15 to 30 years may significantly increase the number of cases of non-overdiagnosed screen-detected lung cancer, does not significantly add to the number of false-positive cases, and saves more lives with an acceptable amount of elevated exposure to radiation and cost.
Copyright © 2015 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Former smokers; Low-dose CT; Lung cancer; Screening; Smoking cessation

Mesh:

Year:  2016        PMID: 26811226      PMCID: PMC4984255          DOI: 10.1016/j.jtho.2015.10.016

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN: 1556-0864            Impact factor:   15.609


  31 in total

1.  Generalizability of epidemiological findings and public health decisions: an illustration from the Rochester Epidemiology Project.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Cynthia L Leibson; Barbara P Yawn; L Joseph Melton; Walter A Rocca
Journal:  Mayo Clin Proc       Date:  2012-02       Impact factor: 7.616

2.  A risk model for prediction of lung cancer.

Authors:  Margaret R Spitz; Waun Ki Hong; Christopher I Amos; Xifeng Wu; Matthew B Schabath; Qiong Dong; Sanjay Shete; Carol J Etzel
Journal:  J Natl Cancer Inst       Date:  2007-05-02       Impact factor: 13.506

3.  Cigarette smoking among adults--United States, 2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2008-11-14       Impact factor: 17.586

4.  Data resource profile: the Rochester Epidemiology Project (REP) medical records-linkage system.

Authors:  Jennifer L St Sauver; Brandon R Grossardt; Barbara P Yawn; L Joseph Melton; Joshua J Pankratz; Scott M Brue; Walter A Rocca
Journal:  Int J Epidemiol       Date:  2012-11-18       Impact factor: 7.196

5.  Clinical features of 5,628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003.

Authors:  Ping Yang; Mark S Allen; Marie C Aubry; Jason A Wampfler; Randolph S Marks; Eric S Edell; Stephen Thibodeau; Alex A Adjei; James Jett; Claude Deschamps
Journal:  Chest       Date:  2005-07       Impact factor: 9.410

6.  Cost-effectiveness of CT screening in the National Lung Screening Trial.

Authors:  William C Black; Ilana F Gareen; Samir S Soneji; JoRean D Sicks; Emmett B Keeler; Denise R Aberle; Arash Naeim; Timothy R Church; Gerard A Silvestri; Jeremy Gorelick; Constantine Gatsonis
Journal:  N Engl J Med       Date:  2014-11-06       Impact factor: 91.245

7.  Chapter 3: Cohort life tables by smoking status, removing lung cancer as a cause of death.

Authors:  Marjorie A Rosenberg; Eric J Feuer; Binbing Yu; Jiafeng Sun; S Jane Henley; Thomas G Shanks; Christy M Anderson; Pamela M McMahon; Michael J Thun; David M Burns
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

8.  Fifty-year trend in incidence rates of bronchogenic carcinoma by cell type in Olmsted County, Minnesota.

Authors:  C M Beard; M B Jedd; L B Woolner; R L Richardson; E J Bergstralh; L J Melton
Journal:  J Natl Cancer Inst       Date:  1988-11-02       Impact factor: 13.506

9.  Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.

Authors:  Martin C Tammemägi; Timothy R Church; William G Hocking; Gerard A Silvestri; Paul A Kvale; Thomas L Riley; John Commins; Christine D Berg
Journal:  PLoS Med       Date:  2014-12-02       Impact factor: 11.069

10.  Current cigarette smoking among adults - United States, 2005-2012.

Authors:  Israel T Agaku; Brian A King; Shanta R Dube
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-01-17       Impact factor: 17.586

View more
  16 in total

1.  Controlled settings for lung cancer screening: why do they matter? Considerations for referring clinicians.

Authors:  A Bharmal; A Crosskill; S Lam; H Bryant
Journal:  Curr Oncol       Date:  2016-12-21       Impact factor: 3.677

2.  Editorial commentary: meeting a paramount challenge.

Authors:  Ping Yang
Journal:  Transl Lung Cancer Res       Date:  2018-04

3.  Sex and Gender Differences in Lung Disease.

Authors:  Patricia Silveyra; Nathalie Fuentes; Daniel Enrique Rodriguez Bauza
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Shared decision-making conversations and smoking cessation interventions: critical components of low-dose CT lung cancer screening programs.

Authors:  Lisa M Lowenstein; Gary M R Deyter; Shawn Nishi; Tianhao Wang; Robert J Volk
Journal:  Transl Lung Cancer Res       Date:  2018-06

5.  5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.

Authors:  Yung-Hung Luo; Lei Luo; Jason A Wampfler; Yi Wang; Dan Liu; Yuh-Min Chen; Alex A Adjei; David E Midthun; Ping Yang
Journal:  Lancet Oncol       Date:  2019-06-26       Impact factor: 41.316

6.  Incorporating both genetic and tobacco smoking data to identify high-risk smokers for lung cancer screening.

Authors:  Guochong Jia; Wanqing Wen; Pierre P Massion; Xiao-Ou Shu; Wei Zheng
Journal:  Carcinogenesis       Date:  2021-06-21       Impact factor: 4.944

7.  Characterizing phenotypic abnormalities associated with high-risk individuals developing lung cancer using electronic health records from the All of Us researcher workbench.

Authors:  Jie Na; Nansu Zong; Chen Wang; David E Midthun; Yuan Luo; Ping Yang; Guoqian Jiang
Journal:  J Am Med Inform Assoc       Date:  2021-10-12       Impact factor: 7.942

Review 8.  Role of sex hormones in lung cancer.

Authors:  Nathalie Fuentes; Miguel Silva Rodriguez; Patricia Silveyra
Journal:  Exp Biol Med (Maywood)       Date:  2021-06-03

Review 9.  Early detection of lung cancer.

Authors:  David E Midthun
Journal:  F1000Res       Date:  2016-04-25

10.  Gene methylation biomarkers in sputum as a classifier for lung cancer risk.

Authors:  Shuguang Leng; Guodong Wu; Donna M Klinge; Cynthia L Thomas; Elia Casas; Maria A Picchi; Christine A Stidley; Sandra J Lee; Seena Aisner; Jill M Siegfried; Suresh Ramalingam; Fadlo R Khuri; Daniel D Karp; Steven A Belinsky
Journal:  Oncotarget       Date:  2017-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.